• Loading stock data...

Latest

Energy | Oct 30, 2024

BP shares fall to lowest since 2022 after sharp drop in the oil major’s third-quarter profit

BP reported its weakest quarterly earnings in nearly four years, attributing the decline to falling crude prices and lower refining margins. For the third quarter of 2024, the British oil major posted an underlying replacement cost profit of $2.3 billion, surpassing analyst expectations of $2.1 billion, but marking a significant drop from the $3.3 billion… Continue reading BP shares fall to lowest since 2022 after sharp drop in the oil major’s third-quarter profit

Mining | Oct 30, 2024

Ivanhoe Mines Delays Q3 2024 Financial Results Call on October 30, 2024 by 15 Minutes; Revised Start Time 10:45am EST

Toronto, Ontario–(Newsfile Corp. – October 30, 2024) – Ivanhoe Mines (TSX: IVN) (OTCQX: IVPAF) will now commence its third quarter 2024 financial results call at 10:45 a.m. Eastern time / 7:45 a.m. Pacific time on October 30, 2024. Link to the results presentation on the company’s website: https://www.ivanhoemines.com/wp-content/uploads/20241030-IVN-Q3-2024-Results-Presentation-vF.pdf. The conference call will conclude with a question-and-answer (Q&A) session.… Continue reading Ivanhoe Mines Delays Q3 2024 Financial Results Call on October 30, 2024 by 15 Minutes; Revised Start Time 10:45am EST

Biotech | Oct 30, 2024

Biogen tops estimates, raises profit guidance as Alzheimer’s drug Leqembi gains traction

Biogen on Wednesday reported third-quarter revenue and adjusted earnings that topped expectations while raising its full-year profit guidance, as sales of its breakthrough Alzheimer’s drug, Leqembi, and other new products gain traction.  Biogen now expects full-year adjusted earnings to come in between $16.10 and $16.60 per share, up from a previous forecast of $15.75 to $16.25… Continue reading Biogen tops estimates, raises profit guidance as Alzheimer’s drug Leqembi gains traction

Biotech | Oct 30, 2024

Eli Lilly stock tumbles after drug giant misses estimates and slashes profit guidance

Eli Lilly’s third-quarter earnings report fell short of Wall Street expectations, leading to a sharp drop in its stock price by over 12%. The company attributed the shortfall to underwhelming sales of its key weight-loss drug, Zepbound, and diabetes medication, Mounjaro, as well as a $2.8 billion charge related to its acquisition of Morphic Holding,… Continue reading Eli Lilly stock tumbles after drug giant misses estimates and slashes profit guidance

US Markets | Oct 30, 2024

U.S. economy grew at a 2.8% pace in the third quarter, less than expected

The U.S. economy demonstrated solid, though slightly below-expected, growth in Q3, with GDP rising at an annualized rate of 2.8% from July through September, as reported by the Commerce Department. This figure fell short of the anticipated 3.1% increase and followed a 3% GDP rise in Q2. Despite high interest rates and concerns that post-COVID… Continue reading U.S. economy grew at a 2.8% pace in the third quarter, less than expected

Technology | Oct 30, 2024

Reddit shares soar 35% on profitability, rosy guidance

Reddit’s shares surged by 35% on Wednesday after the social media company reported unexpected profitability in its third-quarter financial results, along with promising revenue guidance. Reddit’s revenue jumped 68% from the prior year to $348.4 million, surpassing analysts’ expectations of $312.8 million. Additionally, the company reported a net income of $29.9 million, equivalent to 16… Continue reading Reddit shares soar 35% on profitability, rosy guidance

Biotech

Energy

Mining

Technology

US Markets